Filed in archive
Corporate and Industrial News
by ruth on February 21, 2006

Pharmaceutical companies are finding greater value in investing in biotechnology industry, which has proven itself better at advancing compounds than the pharmaceutical industry.
Mark Edwards, managing director of biotech alliance consulting firm Recombinant Capital, cites a good example of how big pharma firms can re-invest their foreign profits and take advantage of the 5.25% tax rate (instead of 35%):
"If you have one-time money, maybe what you want to do is really try to do something that is fundamentally going to change and improve your pipeline prospects akin to what Roche did with Genentech, which is clearly the best investment of all time," he said. "They didn't buy them out and they didn't go product-by-product. They became the first, longest-lasting bio-buddy that's been out there."
Read the full article from the SF Business Times.
Tags:
merger
investment
biotech
expected
repatriate
expected+repatriate
repatriate+100b
pharmaceuticals+ex
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/15861
Mr Wong
Vote for Big Pharmaceuticals Expected to Repatriate $100B:
|
Rating: 8.00 out of 1 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







